Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.

Condreay LD, Qu XA, Anderson J, Compton C, Ghosh S.

Respir Med. 2019 Aug;155:51-53. doi: 10.1016/j.rmed.2019.06.023. Epub 2019 Jun 29.

PMID:
31299468
2.

No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia.

Condreay LD, Gao C, Bradford E, Yancey SW, Ghosh S.

Respir Med. 2019 Aug;155:26-28. doi: 10.1016/j.rmed.2019.07.004. Epub 2019 Jul 5.

PMID:
31295674
3.

ADRB2 p.Thr164Ile association with hospitalization depends upon asthma severity.

Condreay LD, Chiano MN, Li L, Harris E, Fraser DJ, Meyers DA, Bleecker ER, Crim C, Stempel D, Yancey SW, Ghosh S.

J Allergy Clin Immunol. 2019 May;143(5):1962-1965.e4. doi: 10.1016/j.jaci.2019.01.012. Epub 2019 Jan 23. No abstract available.

4.

Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor.

Mosteller M, Condreay LD, Harris EC, Ambery C, Beerahee M, Ghosh S.

Pharmacogenet Genomics. 2014 Dec;24(12):618-21. doi: 10.1097/FPC.0000000000000090.

PMID:
25192553
5.

Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study.

Shinghal R, Barnes A, Mahar KM, Stier B, Giancaterino L, Condreay LD, Black L, McCallum SW.

J Sex Med. 2013 Oct;10(10):2506-17. doi: 10.1111/jsm.12272. Epub 2013 Aug 12.

PMID:
23937679
6.

Genetic analysis of asthma exacerbations.

Anderson WH, Koshy BT, Huang L, Mosteller M, Stinnett SW, Condreay LD, Ortega H.

Ann Allergy Asthma Immunol. 2013 Jun;110(6):416-422.e2. doi: 10.1016/j.anai.2013.04.002.

PMID:
23706709
7.

Genome-wide association study identifies genetic determinants of urine PCA3 levels in men.

Chen Z, Sun J, Kim ST, Groskopf J, Feng J, Isaacs WB, Rittmaster RS, Condreay LD, Zheng SL, Xu J.

Neoplasia. 2013 Apr;15(4):448-53.

8.

The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial.

Chen Z, Greenwood C, Isaacs WB, Foulkes WD, Sun J, Zheng SL, Condreay LD, Xu J.

Carcinogenesis. 2013 Jun;34(6):1260-4. doi: 10.1093/carcin/bgt055. Epub 2013 Feb 7.

9.

Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.

Jin G, Zheng SL, Lilja H, Kim ST, Tao S, Gao Z, Young T, Wiklund F, Feng J, Isaacs WB, Rittmaster RS, Gronberg H, Condreay LD, Sun J, Xu J.

Neoplasia. 2013 Jan;15(1):95-101.

10.

Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history.

Sun J, Na R, Hsu FC, Zheng SL, Wiklund F, Condreay LD, Trent JM, Xu J.

Eur Urol. 2013 Mar;63(3):585-7. doi: 10.1016/j.eururo.2012.11.047. Epub 2012 Dec 5. No abstract available.

11.

Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men.

Jin G, Sun J, Kim ST, Feng J, Wang Z, Tao S, Chen Z, Purcell L, Smith S, Isaacs WB, Rittmaster RS, Zheng SL, Condreay LD, Xu J.

Hum Mol Genet. 2012 Dec 1;21(23):5222-8. doi: 10.1093/hmg/dds361. Epub 2012 Aug 30.

12.

A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.

Newcombe PJ, Reck BH, Sun J, Platek GT, Verzilli C, Kader AK, Kim ST, Hsu FC, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu J.

Genet Epidemiol. 2012 Jan;36(1):71-83. doi: 10.1002/gepi.21600.

13.

Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J.

Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12.

14.

Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance.

Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD.

Hepatol Int. 2011 Jun;5(2):654-63. doi: 10.1007/s12072-010-9228-9. Epub 2011 Jan 5.

15.

Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.

Bourne EJ, Dienstag JL, Lopez VA, Sander TJ, Longlet JM, Hall JG, Kwiatkowski RW, Wright T, Lai CL, Condreay LD.

J Viral Hepat. 2007 Jan;14(1):55-63.

PMID:
17212645
16.

Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.

McGuigan C, Hassan-Abdallah A, Srinivasan S, Wang Y, Siddiqui A, Daluge SM, Gudmundsson KS, Zhou H, McLean EW, Peckham JP, Burnette TC, Marr H, Hazen R, Condreay LD, Johnson L, Balzarini J.

J Med Chem. 2006 Nov 30;49(24):7215-26.

PMID:
17125274
17.

Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.

McGuigan C, Harris SA, Daluge SM, Gudmundsson KS, McLean EW, Burnette TC, Marr H, Hazen R, Condreay LD, Johnson L, De Clercq E, Balzarini J.

J Med Chem. 2005 May 19;48(10):3504-15.

PMID:
15887959
18.

Phosphoramidate protides of carbocyclic 2',3'-dideoxy-2',3'-didehydro-7-deazaadenosine with potent activity against HIV and HBV.

Gudmundsson KS, Wang Z, Daluge SM, Johnson LC, Hazen R, Condreay LD, McGuigan C.

Nucleosides Nucleotides Nucleic Acids. 2004;23(12):1929-37.

PMID:
15628749
19.

HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL.

Hepatology. 2004 Jun;39(6):1694-701. Erratum in: Hepatology. 2004 Sep;40(3):767.

PMID:
15185311
20.

Genotyping anti-hepatitis B virus drug resistance.

Bourne EJ, Gauthier J, Lopez VA, Condreay LD.

Methods Mol Med. 2004;96:379-85. No abstract available.

PMID:
14762283
21.

Phosphoramidate protides of 2',3'-dideoxy-3'-fluoroadenosine and related nucleosides with potent activity against HIV and HBV.

Gudmundsson KS, Daluge SM, Johnson LC, Jansen R, Hazen R, Condreay LD, McGuigan C.

Nucleosides Nucleotides Nucleic Acids. 2003 Oct;22(10):1953-61.

PMID:
14609234
22.

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, de Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA; International Lamivudine Investigator Group.

J Hepatol. 2003 Jun;38(6):818-26.

PMID:
12763376
23.

Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.

Walters KA, Tipples GA, Allen MI, Condreay LD, Addison WR, Tyrrell L.

Antimicrob Agents Chemother. 2003 Jun;47(6):1936-42.

24.

Synthesis of novel 8-substituted carbocyclic analogs of 2',3'-dideoxyadenosine with activity against hepatitis B virus.

Gudmundsson KS, Daluge SM, Condreay LD, Johnson LC.

Nucleosides Nucleotides Nucleic Acids. 2002 Nov-Dec;21(11-12):891-901.

PMID:
12537029
25.

Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels.

Lopez VA, Bourne EJ, Lutz MW, Condreay LD.

J Clin Microbiol. 2002 Jun;40(6):1972-6.

26.

Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.

Gaillard RK, Barnard J, Lopez V, Hodges P, Bourne E, Johnson L, Allen MI, Condreay P, Miller WH, Condreay LD.

Antimicrob Agents Chemother. 2002 Apr;46(4):1005-13.

27.

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN; Asia Hepatitis Lamivudine Study Group.

Hepatology. 2001 Jun;33(6):1527-32.

PMID:
11391543
28.

Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections.

Zhou T, Guo JT, Nunes FA, Molnar-Kimber KL, Wilson JM, Aldrich CE, Saputelli J, Litwin S, Condreay LD, Seeger C, Mason WS.

J Virol. 2000 Dec;74(24):11754-63.

29.

Long-term therapy of chronic hepatitis B with lamivudine.

Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH.

Hepatology. 2000 Oct;32(4 Pt 1):828-34.

PMID:
11003630
30.

Clinical relevance of hepatitis B viral mutations.

Hunt CM, McGill JM, Allen MI, Condreay LD.

Hepatology. 2000 May;31(5):1037-44. Review. No abstract available.

PMID:
10796877
31.

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.

Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ.

Hepatology. 2000 Jan;31(1):207-10.

PMID:
10613747
32.

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.

Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD.

J Infect Dis. 1999 Dec;180(6):1757-62.

PMID:
10558928
33.

Lamivudine as initial treatment for chronic hepatitis B in the United States.

Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA.

N Engl J Med. 1999 Oct 21;341(17):1256-63.

34.

Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine.

Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD.

J Clin Microbiol. 1999 Oct;37(10):3338-47.

35.

Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.

Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD, Mason WS.

Antimicrob Agents Chemother. 1999 Aug;43(8):1947-54.

36.

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.

Tillmann HL, Trautwein C, Bock T, Böker KH, Jäckel E, Glowienka M, Oldhafer K, Bruns I, Gauthier J, Condreay LD, Raab HR, Manns MP.

Hepatology. 1999 Jul;30(1):244-56.

PMID:
10385663
37.

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD.

Hepatology. 1998 Jun;27(6):1670-7.

PMID:
9620341
38.

Lamivudine therapy of WHV-infected woodchucks.

Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, Tennant B, Frick L, Averett D, Condreay LD, Jilbert AR.

Virology. 1998 May 25;245(1):18-32.

39.

Effects of epidermal growth factor on growth of cell lines established from cynomolgus monkey hepatocytes with SV40 T antigen.

Condreay JP, Condreay LD, Huber BE.

In Vitro Cell Dev Biol Anim. 1997 Apr;33(4):228-31. No abstract available.

PMID:
9156333
40.

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA.

Lancet. 1997 Jan 4;349(9044):20-2.

PMID:
8988118
41.

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes.

Condreay LD, Condreay JP, Jansen RW, Paff MT, Averett DR.

Antimicrob Agents Chemother. 1996 Feb;40(2):520-3.

42.

Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.

Condreay LD, Jansen RW, Powdrill TF, Johnson LC, Selleseth DW, Paff MT, Daluge SM, Painter GR, Furman PA, Ellis MN, et al.

Antimicrob Agents Chemother. 1994 Mar;38(3):616-9.

43.

Inhibition of duck hepatitis B virus replication by hypericin.

Moraleda G, Wu TT, Jilbert AR, Aldrich CE, Condreay LD, Larsen SH, Tang JC, Colacino JM, Mason WS.

Antiviral Res. 1993 Mar;20(3):235-47.

PMID:
8470884
44.

Replication of DHBV genomes with mutations at the sites of initiation of minus- and plus-strand DNA synthesis.

Condreay LD, Wu TT, Aldrich CE, Delaney MA, Summers J, Seeger C, Mason WS.

Virology. 1992 May;188(1):208-16.

PMID:
1566574
45.

Characterization of the core promoter and enhancer of duck hepatitis B virus.

Liu C, Condreay LD, Burch JB, Mason W.

Virology. 1991 Sep;184(1):242-52.

PMID:
1871970
46.

Evidence that less-than-full-length pol gene products are functional in hepadnavirus DNA synthesis.

Wu TT, Condreay LD, Coates L, Aldrich C, Mason W.

J Virol. 1991 May;65(5):2155-63.

47.

Efficient duck hepatitis B virus production by an avian liver tumor cell line.

Condreay LD, Aldrich CE, Coates L, Mason WS, Wu TT.

J Virol. 1990 Jul;64(7):3249-58.

48.

Supplemental Content

Loading ...
Support Center